957 The ATR-inhibitor ceralasertib modulates the tumor microenvironment and improves the effect of anti-PDL1 by activating type I IFN pathway

• Dmitry Gabrilovich,
• Simon Barry,
• Mark Cobbold,
• Sehmus Tohumeken,
• Kathy Mulgrew,
• Marta Milo,
• Emilio Sanseviero,
• Devon Taylor,
• Mimi Mai,
• Ali Mostafa,
• Serge Fuchs

Affiliations

Dmitry Gabrilovich

Aff65 grid.251075.40000000119566678The Wistar Institute Philadelphia PA USA

Simon Barry

1AstraZeneca, Cambridge, UK

Mark Cobbold

1AstraZeneca, Gaithersburg, MD, USA

Sehmus Tohumeken

Aff1 0000 0001 2107 3311grid.5330.5Department of Internal Medicine 5, Hematology and OncologyUniversity of Erlangen-Nuremberg Ulmenweg 18 91054 Erlangen Germany

Kathy Mulgrew

1AstraZeneca, Gaithersburg, MD, USA

Marta Milo

1AstraZeneca, Cambridge, UK

Emilio Sanseviero

1AstraZeneca, Gaithersburg, MD, USA

Devon Taylor

1AstraZeneca, Gaithersburg, MD, USA

Mimi Mai

1AstraZeneca, Gaithersburg, MD, USA

Ali Mostafa

1AstraZeneca, Gaithersburg, MD, USA

Serge Fuchs

3University of Pennsylvania, Philadelphia, PA, USA